SBIR/STTR Research Award
A Sensitive, Quantitative, Low-cost, Fluorescence Diagnostic System for Dengue
Award amount
$134,677Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SONG DIAGNOSTIC RESEARCH LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA13-234
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): Dengue is the most rapidly spreading mosquito-borne virus in the world and currently infects 390 million people annually. Studies have shown that existing point-of-care tests have inadequate sensitivity to identify manyindividuals infected with dengue. None have the quantitative capability necessary to aid in the detection of severe dengue, especially in secondary dengue infections. Our approach will provide a low-cost yet quantitative and sensitive system. Our lateralflow immunoassay (LFIA) test will analyze and quantitate the presence of dengue virus non-structural protein (DENV NS1), an analyte that is frequently used to determine a diagnosis of dengue. Fluorescent dyes will be used to improve the limit of detectioncompared to existing rapid tests. A smart phone is utilized for imaging, analysis and automated reporting; the latter feature will simplify disease tracking. A long Stokes shift dye, R-phycoerythrin (PE) will be used as the fluorescent reporter, eith
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients